Zacks Bull and Bear of the Day Highlights: CEMIG, Health Management Associates, Jamba, Starbucks and Caribou Coffee

     Zacks Bull and Bear of the Day Highlights: CEMIG, Health Management
               Associates, Jamba, Starbucks and Caribou Coffee

PR Newswire

CHICAGO, Nov. 27, 2012

CHICAGO, Nov. 27, 2012 /PRNewswire/ --Zacks Equity Research highlights CEMIG
(NYSE:CIG) as the Bull of the Day and Health Management Associates (NYSE:HMA)
as the Bear of the Day. In addition, Zacks Equity Research provides analysis
on Jamba Inc. (Nasdaq:JMBA), Starbucks Corporation (Nasdaq:SBUX) and Caribou
Coffee Company Inc. (Nasdaq:CBOU).


Full analysis of all these stocks is available at

Here is a synopsis of all five stocks:

Bull of the Day:

CEMIG's (NYSE:CIG) 3Q12 results were impressive with its net income
registering a 43% y/y increase and EPADR coming in at US$0.64. Net revenue
grew 19% to US$2.4 billion on the back of a 1.7% increase in electricity sold
to 17,715 GWh. We find the growth prospects for this Brazilian electricity
utility bright.

Operating efficiencies, new projects and strategic acquisitions all bode well
for the future. Moreover, with the growing electricity demand in Brazil as an
important growth booster, the national agency predicts a consumption hike of
about 4.5% in the 2011-2021 timeframe. The nation is growing faster with the
government's increasing keenness to invest heavily in the electric industry.

The company is also doing every bit to increase its capacity in order to meet
the escalating demand. Thus we upgrade our recommendation on the stock from
Neutral to Outperform.

Bear of the Day:

We downgrade our recommendation on Health Management Associates (NYSE:HMA) to
Underperform. Its third-quarter 2012 earnings per share of $0.18 missed the
Zacks Consensus Estimate. We are wary about sustained volume pressure on the
back of sluggish adjusted admissions.

The expected year-over-year decline in same hospital admissions implies
declining volume trends for Health Management, and lackluster demand may
worsen matters. Bad debt is another looming concern and may hurt earnings.

We refrain from suggesting the stock and are waiting to see if the company's
business model and benefits from Obamacare can help Health Management to
overcome the current headwinds and reimbursement uncertainties. We have a
price target of $7.50, which is based on a P/E of approximately 9.3x our
fiscal 2012 EPS estimate.

Latest Posts on the Zacks Analyst Blog:

Jamba Plans to Expand in California

Jamba Juice Company, a subsidiary of Jamba Inc. (Nasdaq:JMBA), is planning a
massive expansion in its home-court California, over the next six-to-seven
years. The company's growth plans include the launch of up to 120 stores in
more than 100 business areas and 25 mall locations across Northern, Central
and Southern California.

Jamba Juice currently operates more than 788 stores. The company plans to open
the new stores through both new and existing franchises. It is also preparing
for the launch of many company-owned stores.

The company's founding state, California, remains an ideal location for
development as it is one of the most populous and widespread state in the U.S.
The promising restaurant industry in this state is a major driving force to
the U.S. economy. In 2012, the total revenue from the restaurant sector in
California is projected around $63.8 billion.

We believe that the development plan will further strengthen Jamba Juice's
position in its prime California market, going forward. However, the company
will likely face stiff competition in that area from its peers like Starbucks
Corporation (Nasdaq:SBUX) and Caribou Coffee Company Inc. (Nasdaq:CBOU).

Jamba has always remained focused on expansion and expects accelerated growth
in both core existing markets as well as new geographic areas. For 2012, Jamba
plans to open 40–50 new stores in the U.S. locations and 15 new stores
internationally. In 2013, the company plans to further speed up its
development process by opening 60 to 80 U.S. and international stores.

Jamba, currently carries a Zacks #3 Rank, which translates into a short-term
'Hold' rating. Our long-term recommendation for the stock remains

Get the full analysis of all these stocks by going to

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.